*ST奥维2025年半年报显示，公司业务涵盖通信设备制造和金属制品。通信设备制造业务方面，公司是 一家从事军队电子信息化、音视频指挥系统、网络通信等业务领域，并提供专业解决方案的重点高新技 术企业。公司金属制品业务属于金属制品行业的细分领域——金属包装材料行业，其下游为金属包装容 器行业。 公告显示，公司2025年前三季度共实现营业收入约3400.25万元，归属于上市公司股东的净利润约-1.88 亿元。 公司同时提示，因触及交易类强制退市情形而终止上市的股票不进入退市整理期，请广大投资者注意投 资风险。 公告显示，公司2024年度营业收入约为2.91亿元，归属于上市公司股东的净利润为-4611.47万元；容诚 会计师事务所（特殊普通合伙）对公司2024年度财务报告出具了无法表示意见的审计报告。公司触及 《深圳证券交易所股票上市规则》第9.3.1条（一）及（三）的规定，公司股票交易自2025年4月29日起 被实施退市风险警示。 1月15日晚，*ST奥维公告称，公司股票当日收盘价格为0.99元/股，若公司股票连续二十个交易日收盘 价均低于1元，公司股票将被深圳证券交易所终止上市交易。 此外，截至2026年1月15 ...

Group 1 - The stock price of *ST Aowei has fallen below 1 yuan, closing at 0.99 yuan per share, which triggers a warning for potential delisting if the price remains below 1 yuan for twenty consecutive trading days [1] - The total market capitalization of the company has been below 500 million yuan for ten consecutive trading days, and if it remains below this threshold for another twenty days, it will face delisting from the Shenzhen Stock Exchange [1] - The company reported an estimated operating revenue of approximately 291 million yuan for the fiscal year 2024, with a net profit attributable to shareholders of -46.11 million yuan, and received an audit report with no opinion from Rongcheng Accounting Firm [1] Group 2 - In the first three quarters of 2025, the company achieved an operating revenue of approximately 34.02 million yuan, with a net profit attributable to shareholders of approximately -188 million yuan [2] - The company operates in the communication equipment manufacturing sector, focusing on military electronic information, audio-video command systems, and network communication, and also engages in the metal packaging materials industry [2]

Core Viewpoint - Jiangsu Wuzhong (600200.SH) is facing imminent delisting risks due to multiple violations, including significant financial losses and operational stagnation, as highlighted in recent announcements and financial reports [1][2][4]. Group 1: Delisting Risks - Jiangsu Wuzhong has issued a risk warning regarding potential delisting due to a face value breach, with a stock price currently at 0.99 yuan, down 89% year-to-date [1][2]. - The company is under investigation by the China Securities Regulatory Commission (CSRC) for major violations, including failure to disclose the actual controller and inflating financial figures from 2018 to 2023 [2][3]. - The company has been identified as having significant non-operational fund occupation by related parties, with amounts soaring from 127 million yuan in 2020 to 1.693 billion yuan in 2023, representing 96.09% of net assets [3]. Group 2: Financial Performance - Jiangsu Wuzhong reported a net loss of 87.468 million yuan for the first three quarters, with revenue dropping by 38.85% to 784 million yuan [1][4]. - The company's pharmaceutical business saw a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth area, is now under threat due to the termination of exclusive distribution rights for a key product [5][6]. - The third quarter alone showed a staggering revenue drop of 63.93% compared to the previous quarter, with a net loss of 43.0502 million yuan, marking a significant operational downturn [5][6].

Core Viewpoint - *ST Gao Hong is facing imminent delisting due to its stock price being below the par value of 1 yuan for 16 consecutive trading days, with a current price of 0.46 yuan per share [1] Company Summary - The main business of *ST Gao Hong includes enterprise information services, IT sales to 3C markets and SMEs, and information services for individual consumers [1] - For the first half of 2025, the company reported an earnings per share of -0.12 yuan and a net profit attributable to shareholders of -140.34 million yuan, with a year-on-year net profit growth rate of -3166.01% [1] - As of August 20, 2025, the number of shareholders stood at 53,000 [1] Regulatory Actions - On August 8, 2025, *ST Gao Hong received a notice from the China Securities Regulatory Commission (CSRC) regarding administrative penalties for severe financial fraud over multiple years [1] - The CSRC found that from 2015 to 2023, *ST Gao Hong inflated its revenue and profits through false trade activities, with a total inflated revenue of approximately 19.8 billion yuan and inflated profits exceeding 76.2 million yuan [2] - The CSRC plans to impose fines exceeding 160 million yuan on *ST Gao Hong and related parties, along with market bans for key individuals involved [2] Market Context - Since August 11, 2025, *ST Gao Hong's stock has experienced continuous trading halts, with 28 trading days of price drops by September 22, 2025 [2] - In 2023, 22 A-share companies have completed delisting procedures, with 6 more currently in the delisting process, indicating a trend of increasing major illegal delistings compared to par value delistings [2] - As of September 21, 2023, over 10 A-share companies have faced administrative penalties from the CSRC for financial fraud, triggering major illegal delisting standards [2]

Core Viewpoint - The company *ST Gao Hong (000851) is at risk of being delisted due to its stock price falling below the par value of 1 yuan for 15 consecutive trading days, with potential for major illegal delisting due to fraudulent activities in its financial reporting [1][2]. Summary by Sections Stock Price and Delisting Risk - As of September 19, 2025, *ST Gao Hong's stock price closed at 0.48 yuan per share, indicating that even with five consecutive trading days of limit-up, it cannot return to the par value of 1 yuan [5]. - The company has been warned that if its stock price remains below 1 yuan for 20 consecutive trading days, it will face delisting according to the Shenzhen Stock Exchange rules [1]. Regulatory Actions and Violations - On August 8, 2025, the company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that its non-public stock issuance in 2020 constituted fraudulent issuance and that its annual reports from 2015 to 2023 contained false records [2][3]. - The fraudulent activities include inflated revenue and profit figures, with reported inflated revenues ranging from 6.94 million yuan to 56.34 million yuan across various years, significantly impacting the reported financial performance [3]. Financial Misrepresentation - The company’s annual reports from 2015 to 2023 showed inflated operating income and costs, with the inflated profits totaling up to 2,190.52 million yuan in 2020, representing 64.88% of the reported profit for that year [3]. - The CSRC's notice also highlighted that the documents related to the 2020 non-public stock issuance included false data from 2018 to 2020, further complicating the company's legal standing [4]. Company Background - *ST Gao Hong, established in 2003 and initiated by the China Academy of Telecommunications Technology, has developed a business structure focusing on digital applications, information services, and IT sales over the past two decades [7].

Core Viewpoint - *ST Gaohong faces the risk of being delisted due to its stock price falling below par value, with a closing price of 0.48 yuan as of September 19, 2025, and has been below 1 yuan for 15 consecutive trading days [1][5]. Group 1: Delisting Risks - The company announced that its stock may be terminated from listing if it continues to trade below 1 yuan for 20 consecutive trading days, as per the Shenzhen Stock Exchange regulations [1]. - The company is also at risk of being subject to mandatory delisting due to significant legal violations, as indicated by a notice from the China Securities Regulatory Commission (CSRC) regarding fraudulent issuance of shares and false financial reporting from 2015 to 2023 [2]. Group 2: Financial Misreporting - The CSRC's notice revealed that the company inflated its reported revenue and costs significantly over several years, with inflated revenues ranging from 6.94 million yuan to 56.34 million yuan, constituting up to 49.38% of reported revenues in certain years [3]. - The inflated profits reported by the company also showed substantial discrepancies, with inflated profit totals reaching as high as 2,190.52 million yuan, representing 64.88% of the reported profit in one year [3]. Group 3: Recent Developments - The company’s non-public stock issuance in 2020 was found to contain false data, leading to accusations of fraudulent issuance, with a total fundraising amount of 1.25 billion yuan approved by the CSRC [4]. - The stock has experienced significant volatility, with a cumulative price drop exceeding 12% over three consecutive trading days in September 2025 [4].

Core Viewpoint - The company, 大唐高鸿网络股份有限公司, has issued a risk warning regarding the potential termination of its stock listing due to its share price falling below the par value of 1 yuan per share, which was recorded at 0.98 yuan per share for the first time [1][2]. Group 1: Reasons for Potential Termination of Listing - The company’s stock may be delisted if it trades below 1 yuan for 20 consecutive trading days, as per the Shenzhen Stock Exchange listing rules [2]. - The company has been identified in an administrative penalty notice for fraudulent issuance of shares in 2020 and for false records in annual reports from 2015 to 2023, which may lead to mandatory delisting [4][5]. Group 2: Disclosure of Termination Risk - The company is required to disclose the risk of potential delisting on the next trading day after its stock price first falls below 1 yuan, and must continue to disclose this risk if the price remains below 1 yuan for 10 consecutive trading days [2][3]. Group 3: Additional Information - The company’s stock has been under risk warning since August 11, 2025, due to the aforementioned issues, and it has received an audit opinion indicating an inability to express a view on its financial statements [5].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of forced delisting due to major violations and financial issues, including false reporting of revenue and profits from 2020 to 2023 [4]. Group 1: Major Violation Delisting Risk - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for falsely inflating operating income, costs, and profits, which may lead to forced delisting [4]. - The company’s stock has been under risk warning since July 14, 2025, due to the potential for major violations leading to termination of listing [1][4]. Group 2: Financial Delisting Risk - The 2024 financial report received a disclaimer of opinion from the auditing firm, triggering financial delisting risks under the Shanghai Stock Exchange rules [1][2]. - The company is currently under risk warning due to financial issues, including the inability to express an opinion on internal controls [2]. Group 3: Other Risk Warnings - The company is facing additional risk warnings due to non-operational fund occupation by related parties, which violates stock exchange regulations [2]. - The company has also encountered operational risks, including a contract termination with a medical product distributor, affecting sales [2]. Group 4: Investor Advisory - The company urges investors to be cautious and rational in their investment decisions, especially given the recent abnormal stock price fluctuations that do not align with deteriorating fundamentals [4].

Core Points - *ST Suwu's stock closed at 0.99 CNY per share on August 14, which is below the 1 CNY threshold [1] - According to the Shanghai Stock Exchange rules, if a company's stock price remains below 1 CNY for 20 consecutive trading days, it may face delisting [1] - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, leading to a risk warning being implemented from July 14 [1] - If the CSRC's final decision confirms significant violations, the company's stock will be subject to mandatory delisting [1]

Group 1 - The core point of the article is that Jiyuan Holdings Group Co., Ltd. (*ST Jiyuan) will be delisted from the Shenzhen Stock Exchange on May 29, 2025, due to triggering mandatory delisting rules after its stock price remained below 1 yuan for 20 consecutive trading days [1][3] - The company has experienced continuous losses since 2019, with a cumulative net profit loss exceeding 3.2 billion yuan from 2019 to 2023 [3] - Jiyuan Holdings has faced significant goodwill impairment risks, totaling over 1.5 billion yuan from 2019 to 2024, which has directly contributed to its net profit losses [3] Group 2 - The company was originally known as Tonghua Shuanglong Chemical Co., Ltd. and transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical [3] - Since its rebranding in 2017, the company has aggressively pursued mergers and acquisitions, acquiring over ten companies within three years, leading to a dual business model of "chemicals + pharmaceuticals" [3] - In 2024, the company's revenue declined by 3.69%, and its losses expanded to 439 million yuan [3] Group 3 - As of 2025, a total of 11 companies have been delisted from the A-share market, with *ST Jiyuan being one of them, alongside others like *ST Meixun and *ST Bo Xin [4] - The reasons for delisting include breaches of face value, market value, voluntary delisting applications, and forced delisting due to major violations [4]